Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Destiny Pharma has appointed Dr Stephanie Bewick as chief business officer.
Dr Bewick joins the clinical stage biotech company with immediate effect.
She was most recently vice president of business at Summit Therapeutics.
She holds a BSc (Hons) Neuroscience from the University of Edinburgh and a PhD from the University of Bristol.
At 1:46pm: (LON:DEST) Destiny Pharma Plc share price was 0p at 68.5p